Top in women's health: IVF may raise morbidity odds; RNA platform predicts fetal growth
Researchers found that maternal morbidity risks were higher among women who underwent in vitro fertilization or intrauterine insemination vs. those who had unassisted pregnancies.
“Public health initiatives promoting elective single embryo transfer and counseling on maternal morbidity risks associated with medically assisted reproduction-related multifetal pregnancies can guide safer treatment choices, potentially lowering maternal morbidity rates and related costs,” Alina Pelikh, PhD, senior research fellow in demography and deputy research director at the Centre for Longitudinal Studies at the Social Research Institute at the University College London, and colleagues wrote.
It was the top story in women’s health last week.
In another top story, Healio spoke with an expert about their presentation from The Pregnancy Meeting, where they shared findings on an RNA platform that assessed millions of maternal, fetal and placental RNA messages to help predict pregnancy complications.
Read these and more top stories in women’s health below:
IVF, intrauterine insemination tied to higher maternal morbidity odds
Women who underwent in vitro fertilization or intrauterine insemination were more likely to experience maternal morbidity compared with unassisted pregnancies, according to findings published in Obstetrics & Gynecology. Read more.
Q&A: RNA platform predicts severe fetal growth restriction months before birth
An RNA platform successfully predicted fetal growth restriction within the second trimester of pregnancy, independent of other risk factors, according to a presentation at The Pregnancy Meeting. Read more.
‘Substantial opportunity’ to prevent postpartum smoking relapse, improve maternal health
Smoking patterns during preconception, pregnancy and the postpartum period vary based on maternal age, race and ethnicity, geographical location and insurance type, according to a research letter published in JAMA Network Open. Read more.
Q&A: Navigating management of women with high-risk HPV but normal cytology
Fewer than half of women who tested positive for HPV with negative cytological findings returned for a surveillance co-test within 1 year as recommended, yet more than half of those who received testing had HPV persistence or progression. Read more.
Hormone therapy use higher among midlife active-duty servicewomen, but gaps remain
Use of menopausal hormone therapy among midlife active-duty servicewomen in the U.S. is twice as high as the general population but lower than women veterans, suggesting those who may derive the most benefit from hormone therapy are not receiving it. Read more.